Business
Result of EGM
Result of EGM.
About this update from Valirx Plc
[{"type":"text","content":"\n \n\n\n\n\n\nRNS Number : 4434C ValiRx PLC 07 March 2011 \n \n\n7 March 2011\nValiRx Plc\n(\"ValiRx\" or the \"Company\")\n \nRESULT OF GENERAL MEETING\n \nValiRx (AIM: VAL), the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that at the General Meeting of the Company held earlier today, all resolutions were duly passed.\n \n \nEnquiries:\n \n\n\n\n\nValiRx plc\n\n\nwww.valirx.com\n\n\n\n\nDr. Satu Vainikka\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\n\n\n\n\n\n\n\n\nHybridan LLP\nBroker\n\n\n\n\n\n\n\nClaire Noyce\n\n\nTel: +44 (0) 20 7947 4350\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP \nNominated Adviser\n\n\n\n\n\n\n\nLiam Murray / Avi Robinson\n\n\n Tel:+44 (0) 20 7148 7900\n\n\n\n\n\n\n\n\n\n\n\n\nPeckwater PR\n\n\n\n\n\n\n\nTarquin Edwards\n\n\nTel: +44 (0) 7879 458 364\n\n\n\n\n\n\n\[email protected]\n\n\n\n\n \nNotes for Editors\n \nValiRx Plc\nValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.\n \nThe Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest. \n \nThe Company operates through the following divisional companies:\n· ValiMedix is the sales and distribution division of ValiRx\n· ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers. Of particular note is GeneICE, ValiRx's technology for controlling rebellious genes, which was awarded a Eurostars grant to the value of €1.2 million to fund...